ESTROGEN AGONIST/ANTAGONIST METABOLITES

1. A metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol selected from the group consisting of: and stereoisomers, tautomers, regio and configurational isomers thereof and pharmaceutically acceptable salts thereof. 2. A method for treating osteoporosis, breast cancer, hyperlipidemia, atherosclerosis, Alzheimer's disease, cataracts, loss of libido, male sexual dysfunction, colon cancer, skin wrinkles, autoimmune disease, alopecia, acne, cardiovascular disease, diabetes, endometriosis, female sexual dysfunction, hyperglycemia, obesity, obsessive compulsive disorder, premenstrual syndrome, prostatic carcinoma, benign prostatic hyperplasia, pulmonary hypertension, reperfusion damage, rheumatoid arthritis, osteoarthritis, seborrhea, senile gynecomastia, testosterone deficiency and conditions responsive to testosterone elevation, Turner's syndrome, uterine fibrosis, atrophic vaginitis, incontinence, uterine cancer, hirsutism, bulimia, anorexia, hypoactive sexual desire, sexual arousal disorder, dyspareunia, vagismus, prolapse, urinary tract infections, stroke, myocardial infarction, acute or chronic renal failure, peripheral arterial occlusive disease, Raynaud's Phenomenon, and treating cancers of the ovary, liver, and pancreas, as well as desmoid cancer, glioma, and renal cell carcinoma, the promotion of wound healing. increasing the frequency of orgasm, comprising administering to a subject in need thereof, an effective amount of a metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol selected from the group consisting of: and stereoisomers, tautomers, regio and configurational isomers thereof and pharmaceutically acceptable salts thereof. 3. A pharmaceutical composition comprising a metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol as defined in claim 2 and pharmaceutically acceptable carrier, excipient or diluent.